Fresnillo (LSE: FRES): Can the world’s largest silver miner hold its record gains as 2026 output dips?
TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record
Read More Pharma Industry News Is Avacta Therapeutics changing the rules of chemotherapy? Inside the Phase 1a findings that impressed ESMO Avacta Therapeutics’ Phase 1a trial data shows faridoxorubicin’s tumor-targeted action and cardiac safety. Explore the implications for pre|CISION in solid tumors. byVenkateshOctober 21, 2025